Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.83 |
| ▸ | KDR | P35968 | 17/20 | 0.83 |
| ▸ | IGF1R | P08069 | 13/20 | 0.83 |
| ▸ | INSR | P06213 | 2/20 | 0.80 |
| ▸ | AURKA | O14965 | 1/20 | 0.80 |
| ▸ | JAK2 | O60674 | 1/20 | 0.80 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.80 |
| ▸ | ABL1 | P00519 | 1/20 | 0.80 |
| ▸ | LCK | P06239 | 1/20 | 0.80 |
| ▸ | RET | P07949 | 1/20 | 0.80 |
| ▸ | KIT | P10721 | 1/20 | 0.80 |
| ▸ | PIM1 | P11309 | 1/20 | 0.80 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.80 |
| ▸ | SRC | P12931 | 1/20 | 0.80 |
| ▸ | PRKACA | P17612 | 1/20 | 0.80 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.80 |
| ▸ | JAK1 | P23458 | 1/20 | 0.80 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.80 |
| ▸ | AKT1 | P31749 | 1/20 | 0.80 |
| ▸ | AKT2 | P31751 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL199381 | 0.91 | MET (1.00) | METKDRIGF1RINSRAURKA | |
| SCHEMBL2158221 | 0.89 | MET (0.90) | METKDRIGF1RINSRAURKA | |
| SCHEMBL12004043 | 0.88 | MET (0.84) | METKDRIGF1RINSRAURKA | |
| SCHEMBL199084 | 0.88 | MET (0.85) | METKDRIGF1RINSRAURKA | |
| Ningetinib SCHEMBL29392305 | 0.88 | MET (1.00) | METKDRIGF1RINSRAURKA | |
| Ningetinib SCHEMBL12003786 | 0.88 | MET (1.00) | METKDRIGF1RINSRAURKA | |
| Ningetinib SCHEMBL29366570 | 0.88 | MET (1.00) | METKDRIGF1RINSRAURKA | |
| SCHEMBL12003909 | 0.87 | MET (1.00) | METKDRIGF1RINSRAURKA | |
| SCHEMBL12003908 | 0.87 | MET (1.00) | METKDRIGF1RINSRAURKA | |
| Ningetinib SCHEMBL12003712 | 0.87 | MET (0.99) | METKDRIGF1RINSRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532657-B9 | Compounds and methods of use | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-04-19 | — | — | EP | disclosed |
| US-9598400-B2 | Substituted quinoline compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2532657-B1 | Compounds and methods of use | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-08-31 | — | — | EP | disclosed |
| EP-2680886-B1 | SUBSTITUTED QUINOLINE COMPOUNDS | CALITOR SCIENCES LLC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2408300-B1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-05-11 | — | — | EP | disclosed |
| US-20150342945-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-12-03 | — | — | US | disclosed |
| US-9133162-B2 | Substituted quinoline compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-09-15 | — | — | US | disclosed |
| EP-2680886-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8426585-B2 | Compounds comprising a spiro-ring | Xi, Ning (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120315247-A1 | COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2012-12-13 | — | — | US | disclosed |
| US-8293897-B2 | Compounds comprising a spiro-ring and methods of use | Xi, Ning (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2012118632-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | XI NING (US) | 2012-09-07 | — | — | WO | disclosed |
| US-20120219522-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | XI, Dr. Ning (US) | 2012-08-30 | — | — | US | disclosed |
| US-8232294-B2 | Amino ester derivatives, sailts thereof and methods of use | Xi, Ning (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2408300-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd (CN) | 2012-01-25 | — | — | EP | disclosed |
| EP-2340244-A1 | COMPOUNDS AND METHODS OF USE | Xi, Ning (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010111063-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | XI NING (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100239576-A1 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| WO-2010045095-A1 | COMPOUNDS AND METHODS OF USE | XI NING (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093727-A1 | COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342945-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | MKI67, MCL1, NRAS | MET 997/4885KDR 577/4885IGF1R 1984/4885 |
| US-20100239576-A1 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE | SRC, BCAT1, BCAT2 | MET 185/4885KDR 958/4885IGF1R 599/4885 |
| US-20100093727-A1 | COMPOUNDS AND METHODS OF USE | PRKDC, PRKACA, PRKX | MET 302/4885KDR 600/4885IGF1R 493/4885 |
| US-20120315247-A1 | COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE | CDC42BPG, HRAS, PTPRJ | MET 732/4885KDR 728/4885IGF1R 614/4885 |
| US-20120219522-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | MKI67, MCL1, NRAS | MET 997/4885KDR 577/4885IGF1R 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.